Clinical Trials for Eikon Therapeutics

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Eikon Therapeutics

Clinical Trials (5)

NCT06697301
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
PHASE2/PHASE3Recruiting
740 participants
Started: May 22, 2025 · Completed: Dec 31, 2040
1 condition2 sponsors57 locations
NCT06907043
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
PHASE1/PHASE2Recruiting
130 participants
Started: Apr 30, 2025 · Completed: Dec 31, 2028
1 condition2 sponsors10 locations
NCT06246110
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
PHASE2Recruiting
70 participants
Started: Feb 6, 2024 · Completed: Dec 31, 2027
1 condition1 sponsor39 locations
NCT06253130
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
70 participants
Started: Dec 11, 2023 · Completed: Dec 1, 2026
1 condition2 sponsors24 locations
NCT03915678
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
PHASE2Recruiting
247 participants
Started: Mar 31, 2021 · Completed: Dec 31, 2027
7 conditions4 sponsors11 locations